Our
Clients
: Aug, 2020
: 100
:
Peptide Cancer Vaccine Market: Description
Peptide Cancer Vaccine provides tumour specific T-cells to control or eradicate cancer. The vaccine contains tumour antigens in the form of short or long amino acid sequences. The usage of Peptide Cancer Vaccine is to control tumour growth in mouse models which is expected to propel the growth of Peptide Cancer Vaccine Market. In the recent past, results of clinical trials performed using peptide cancer vaccine has shown negative outcomes.
The advantages involved in the preparation and usage of peptide vaccine are easy to synthesize, cost-effective, and easy to prepare. Its application in clinical practice, flexibility in changing antigen, and lower risk of antigen-induced anaphylaxis are expected to increase the growth of the peptide cancer vaccine market in the near future.
Source: WMR
Peptide Cancer Vaccine Market: Overview
The revenue of the Peptide Cancer Vaccine Market was USD 4,720 million in the year 2022. It is expected to reach USD 10,070 million with a Compound Annual Growth Rate (CAGR) of 11.2% by the end of 2032.
Due to an increase in the prevalence of cancer and failure of conventional methods for the treatment of the disease, it has effectively led to an increase in demand for new immunotherapy-based therapies, such as peptide vaccine. Manufacturers are also involved in mergers and acquisitions and new product launches in the peptide cancer vaccine market to cater to the increasing demand for vaccines. Further, the industry is adopting sustainable solutions for vaccine which can lead to further growth.
Source: WMR
Peptide Cancer Vaccine Market: Key Trends
Major Players Emphasize on the Research Activities to Develop Peptide Vaccine to grow the Market Demand
Peptide Cancer Vaccines have various advantages such as, they are easy to prepare, easy to synthesize, cost-effective, helpful in clinical practices, have lower risk of antigen-induced anaphylaxis, and are flexibility in changing antigen. All these advantages are responsible for increasing the growth of Peptide Cancer Vaccine Market in coming years. In addition, various key players are also investing in research activities to produce Peptide Cancer Vaccines because of its beneficial advantages. We can consider an example of, Boston Biomedical, Inc., which is a global developer of novel cancer therapeutics that announced the evaluation of DSP-7888, an investigational WT1 cancer peptide vaccine to investigate the safety, tolerability, and determination of the recommended phase 2 dose of DSP-7888 in patients.
Provision of Healthy Features of Peptide Vaccine than Conventional Therapies that drive the Market
The Peptide Cancer Vaccines have good features in terms of better safety and tolerance than conventional methods such as, immune checkpoint inhibitors and chemotherapy. The growing prevalence of cancer and presence of good characteristics of these vaccines are accelerating the demand for Peptide Cancer Vaccine Market during the given time period. According to International Agency for Research on Cancer, worldwide around 19.3 million new cancer cases are estimated and almost 10.0 million cancer deaths have occurred in 2020. Among these, major cases observed for breast, lung, colorectal, prostate, and stomach cancers. It has shown an increase in the demand for Peptide Cancer Vaccine Market in coming years.
Impact of Covid-19 on the Market
The COVID-19 pandemic has had a significant impact on the healthcare industry, including the peptide cancer vaccine market. However, with the ongoing vaccination campaigns and the gradual reopening of economies, the peptide cancer vaccine market is expected to recover in the coming years. Here are some potential factors that could contribute to the recovery of the peptide cancer vaccine market from COVID-19:
Increasing awareness about cancer and its treatment: The COVID-19 pandemic has put a spotlight on the importance of healthcare, and as a result, people are becoming more aware of the risks associated with cancer. This could lead to an increase in demand for cancer treatments, including peptide cancer vaccines.
Government initiatives and funding: Governments across the world are investing heavily in healthcare infrastructure and research to combat the COVID-19 pandemic. This could result in increased funding for cancer research and vaccine development, which would ultimately benefit the peptide cancer vaccine market.
Improved healthcare access: The pandemic has highlighted the importance of universal healthcare and access to treatments for all. This could lead to improved healthcare access for cancer patients, which would increase demand for peptide cancer vaccines.
Technological advancements: The pandemic has accelerated the adoption of telemedicine and digital healthcare solutions, which could improve the efficiency and accessibility of cancer treatments, including peptide cancer vaccines.
In conclusion, while the COVID-19 pandemic has had a significant impact on the peptide cancer vaccine market, there are several factors that could contribute to its recovery in the coming years.
Peptide Cancer Vaccine Market: Segmentation Analysis
Cancer Vaccine Market Key Players:
TapImmune
Merck
BrightPath Biotherapeutics
Sellas
BioLife Science
Boston Biomedical
VAXON Biotech
Lytix Biopharma
ISA Pharmaceuticals
Generex Biotechnology
Onco Therapy Science
Enzo Life Science
Antigen Express
Immatics Biotechnologies
Immune Design
Immunomedics
Galena Biopharma
Generex Biotechnology Corporation
Ultimovacs
Peptide Cancer Vaccine Market based on Product Type:
Personalized Peptide Vaccine
Peptide-Pulsed Dendritic Cancer Vaccine
Peptide Cocktail Type
Multivalent Peptide Vaccine
Others
Personalized Peptide Vaccines are immunotherapeutic approach and is based on the administration of multiple cancer peptides. It is developed from patients own tumor cells. While, peptide-pulsed dendritic cancer vaccine is used to treat patients with stage IV melanoma.
Source: WMR
Peptide Cancer Vaccine Market based on Pipeline Phase
Research
Preclinical
Phase-I
Phase I/II
Phase-II
Phase-III
The research segment is anticipated to amplify significantly over the forecast duration due to rise in government funding to facilitate research and development activities in the field.
Peptide Cancer Vaccine Market based on Application:
Breast Cancer
Lung Cancer
Gastric Cancer
Prostate Cancer
Pancreatic Cancer
Colorectal Cancer
Breast Cancer is the type of cancer that forms in the cells of the breasts. It can occur in women and rarely in men. The symptoms of breast cancer are that there is a lump in the breast, bloody discharge from the nipple, and changes in the shape or texture of the nipple or breast. Whereas, Lung Cancer is a cancer that begins in the lungs and mostly occurs in people who smoke. The two types of lung cancer include non-small cell lung cancer and small cell lung cancer. Causes of lung cancer includes smoking, second-hand smoke, exposure to certain toxins and family history.
Peptide Cancer Vaccine Market: Regional Analysis
Emerging economies that includes North America, Europe, Asia Pacific and Latin America are set to collect most of the growth in the Peptide Cancer Vaccine Market in coming years.
North America: North America is one of the largest markets for peptide cancer vaccines, with the United States being the primary contributor. The high prevalence of cancer in the region and the presence of major pharmaceutical companies in the US are the key drivers for market growth in North America.
Europe: Europe is another major market for peptide cancer vaccines, with countries like Germany, France, and the UK being major contributors. The high incidence of cancer and the presence of established healthcare infrastructure in the region are the key factors driving the market's growth in Europe.
Asia Pacific: The Asia Pacific region is expected to witness significant growth in the peptide cancer vaccine market due to the high prevalence of cancer in countries like China and India. Additionally, the increasing healthcare expenditure and growing awareness about cancer treatments are driving market growth in the region.
Latin America: The Latin America peptide cancer vaccine market is expected to witness steady growth due to the increasing incidence of cancer in the region and the presence of established pharmaceutical companies.
Middle East and Africa: The Middle East and Africa region are expected to witness moderate growth in the peptide cancer vaccine market due to the increasing incidence of cancer in the region and the rising healthcare expenditure.
Report Scope:
Peptide Cancer Vaccine Market Forecast Years: 2023-2032
Peptide Cancer Vaccine Market 2022: USD 4,720 million
Peptide Cancer Vaccine Market 2032: USD 10,070 million
Peptide Cancer Vaccine Market CAGR: 11.2%
Key Segments: Product Type, Pipeline Phase, and Application
Key Regions and Countries: North America; Europe; Asia Pacific; Latin America
1. Global Peptide Cancer Vaccine Market Introduction and Market Overview
1.1. Objective of the Market Research Study
1.2. Peptide Cancer Vaccine Market Definition & Description
1.3. Research Data Parameters & Reporting Timelines
1.3.1. Historical Data Reporting Years 2020 to 2021
1.3.2. Projected Data Reporting Years 2023 to 2033
1.3.3. Reporting Data Parameters Value (US$ Million)
1.4. Global Peptide Cancer Vaccine Market Scope and Market Estimation
1.4.1. Global Peptide Cancer Vaccine Overall Market Size (Us$ Million), Market CAGR (%), Market Estimates & Forecast (2020 to 2033)
1.4.2. Global Peptide Cancer Vaccine Market Revenue Share (%) and Growth Rate (Y-o-Y) from 2020 to 2033
1.5. Peptide Cancer Vaccine Market Segmentation
1.5.1. Type of Global Peptide Cancer Vaccine Market
1.5.2. Pipeline Phase of Global Peptide Cancer Vaccine Market
1.5.3. Application of Global Peptide Cancer Vaccine Market
1.5.4. Key Regions of Global Peptide Cancer Vaccine Market
2. Global Peptide Cancer Vaccine Market - Executive Summary
2.1. Global Peptide Cancer Vaccine Market Summary & Snapshot
2.2. Global Peptide Cancer Vaccine Market, By Type (Us$ Million)
2.3. Global Peptide Cancer Vaccine Market, By Pipeline Phase (Us$ Million)
2.4. Global Peptide Cancer Vaccine Market, By Application (Us$ Million)
2.5. Global Peptide Cancer Vaccine Market, By Geography (Us$ Million)
2.6. Global Peptide Cancer Vaccine Market Outlook & Future Opportunities
3. Peptide Cancer Vaccine Market Trends, Outlook, and Factors Analysis
3.1. Global Peptide Cancer Vaccine Market Industry Development Trends under COVID-19 Outbreak
3.1.1. Global COVID-19 Status Overview
3.1.2. Influence of COVID-19 Outbreak on Global Peptide Cancer Vaccine Market Industry Development
3.1.3. Pre & Post COVID-19 Trends and Scenarios
3.2. Market Dynamics (Growth Impacting Factors & Rationales)
3.2.1. Drivers
3.2.1.1. Increasing Cancer patients population Worldwide.
3.2.1.2. Increase in Healthcare Concern and change in lifestyle.
3.2.1.3. Rising cases of the SARS-CoV-2 infection and other disease worldwide
3.2.1.4. Driver 4
3.2.1.5. Driver 5
3.2.2. Restraints
3.2.2.1. Obstacles such as lack of cancer vaccines in rural places, as well as the necessity for specialized storage and transportation.
3.2.3. Opportunities
3.2.3.1. Expansion of healthcare industries like never like before due to COVID-19
3.2.3.2. Increasing government investment in research and development
3.2.3.3. Increasing demand in vaccine manufacturing
3.2.3.4. Opportunity 4
3.2.3.5. Opportunity 5
3.2.4. Impact Analysis of Drivers and Restraints
3.3. Ecosystem/ Value Chain Analysis
3.4. Porters Five Forces Analysis
3.5. SWOT Analysis
3.6. PEST Analysis
3.7. Average Selling Prices and Pricing Trends Analysis of Peptide Cancer Vaccine Market
3.8. Technological Roadmap
3.9. Key Investment Pockets of Peptide Cancer Vaccine Market
3.9.1. By Type
3.9.2. By Pipeline Phase
3.9.3. By Application
3.9.4. By Regions
4. Global Peptide Cancer Vaccine Market: Estimates & Historic Trend Analysis (2020 to 2021)
4.1. Global Peptide Cancer Vaccine Market, 2020 2021 (Us$ Million)
4.2. Global Peptide Cancer Vaccine Market, By Type, 2020 to 2021 (Us$ Million)
4.3. Global Peptide Cancer Vaccine Market, By Pipeline Phase, 2020 to 2021 (Us$ Million)
4.4. Global Peptide Cancer Vaccine Market, By Application, 2020 to 2021 (Us$ Million)
4.5. Global Peptide Cancer Vaccine Market, By Region, 2020 to 2021 (Us$ Million)
5. Global Peptide Cancer Vaccine Market Estimates & Forecast Trend Analysis, by Type
5.1. Global Peptide Cancer Vaccine Market Share (%) Estimates and Forecasts, By Type, 2023 & 2033
5.2. Global Peptide Cancer Vaccine Market Size (Us$ Million) Estimates and Forecasts, by Type, 2023 to 2033
5.2.1. Personalized Peptide Vaccine
5.2.2. Peptide-Pulsed Dendritic Cancer Vaccine
5.2.3. Peptide Cocktail Type
5.2.4. Multivalent Peptide Vaccine
5.2.5. Others
6. Global Peptide Cancer Vaccine Market Estimates & Forecast Trend Analysis, by Pipeline Phase
6.1. Global Peptide Cancer Vaccine Market Share (%) Estimates and Forecasts, By Pipeline Phase, 2023 & 2033
6.2. Global Peptide Cancer Vaccine Market (Us$ Million) Estimates and Forecasts, by Pipeline Phase, 2023 to 2033
6.2.1. Research
6.2.2. Preclinical
6.2.3. Phase-I
6.2.4. Phase-I/II
6.2.5. Phase-II
6.2.6. Phase-III
7. Global Peptide Cancer Vaccine Market Estimates & Forecast Trend Analysis, by Application
7.1. Global Peptide Cancer Vaccine Market Share (%) Estimates and Forecasts, By Application, 2023 & 2033
7.2. Global Peptide Cancer Vaccine Market (Us$ Million) Estimates and Forecasts, by Application, 2023 to 2033
7.2.1. Colorectal Cancer
7.2.2. Lung Cancer
7.2.3. Pancreatic Cancer
7.2.4. Gastric Cancer
7.2.5. Prostate Cancer
7.2.6. Breast Cancer
7.2.7. Others
8. Global Peptide Cancer Vaccine Market Analysis and Forecast, by Region
8.1. Global Peptide Cancer Vaccine Market Share (%) Estimates and Forecasts, By Region, 2023 & 2033
8.2. Global Peptide Cancer Vaccine Market (Us$ Million) Estimates and Forecasts, by Region, 2023 to 2033
8.2.1. North America
8.2.2. Europe
8.2.3. Asia Pacific
8.2.4. Middle East and Africa
8.2.5. Latin America
9. North America Peptide Cancer Vaccine Market: Estimates & Forecast Trend Analysis
9.1. North America Peptide Cancer Vaccine Market Assessments & Key Findings
9.2. North America Peptide Cancer Vaccine Market Share (%) Estimates and Forecasts, 2023 & 2033
9.3. North America Peptide Cancer Vaccine Market Size Estimates and Forecast (Us$ Million) (2023 to 2033)
9.3.1. By Type
9.3.2. By Pipeline Phase
9.3.3. By Application
9.3.4. By Major Country
9.3.4.1. The U.S.
9.3.4.2. Canada
10. Europe Peptide Cancer Vaccine Market: Estimates & Forecast Trend Analysis
10.1. Europe Peptide Cancer Vaccine Market Assessments & Key Findings
10.2. Europe Peptide Cancer Vaccine Market Share (%) Estimates and Forecasts, 2023 & 2033
10.3. Europe Peptide Cancer Vaccine Market Size Estimates and Forecast (Us$ Million) (2023 to 2033)
10.3.1. By Type
10.3.2. By Pipeline Phase
10.3.3. By Application
10.3.4. By Major Country
10.3.4.1. Germany
10.3.4.2. The U.K.
10.3.4.3. France
10.3.4.4. Italy
10.3.4.5. Spain
10.3.4.6. Rest of Europe (includes all other European countries)
11. Asia Pacific Peptide Cancer Vaccine Market: Estimates & Forecast Trend Analysis
11.1. Asia Pacific Peptide Cancer Vaccine Market Assessments & Key Findings
11.2. Asia Pacific Peptide Cancer Vaccine Market Share (%) Estimates and Forecasts, 2023 & 2033
11.3. Asia Pacific Peptide Cancer Vaccine Market Size Estimates and Forecast (Us$ Million) (2023 to 2033)
11.3.1. By Type
11.3.2. By Pipeline Phase
11.3.3. By Application
11.3.4. By Major Country
11.3.4.1. China
11.3.4.2. Japan
11.3.4.3. India
11.3.4.4. ASEAN
11.3.4.5. South Korea
11.3.4.6. Rest of Asia Pacific (includes all other Asia Pacific countries)
12. Middle East & Africa Peptide Cancer Vaccine Market: Estimates & Forecast Trend Analysis
12.1. Middle East & Africa Peptide Cancer Vaccine Market Assessments & Key Findings
12.2. Middle East & Africa Peptide Cancer Vaccine Market Share (%) Estimates and Forecasts, 2023 & 2033
12.3. Middle East & Africa Peptide Cancer Vaccine Market Size Estimates and Forecast (Us$ Million) (2023 to 2033)
12.3.1. By Type
12.3.2. By Pipeline Phase
12.3.3. By Application
12.3.4. By Major Country
12.3.4.1. GCC
12.3.4.2. South Africa
12.3.4.3. Egypt
12.3.4.4. Rest of Middle East & Africa (includes all other Middle East & Africa countries)
13. Latin America Peptide Cancer Vaccine Market: Estimates & Forecast Trend Analysis
13.1. Latin America Market Assessments & Key Findings
13.2. Latin America Peptide Cancer Vaccine Market Share (%) Estimates and Forecasts, 2023 & 2033
13.3. Latin America Peptide Cancer Vaccine Market Size Estimates and Forecast (Us$ Million) (2023 to 2033)
13.3.1. By Type
13.3.2. By Pipeline Phase
13.3.3. By Application
13.3.4. By Major Country
13.3.4.1. Brazil
13.3.4.2. Mexico
13.3.4.3. Rest of Latin America (includes all other Latin America countries)
14. Competitive Landscape
14.1. Market Revenue Share Analysis (%), by Major Players (2022)
14.2. Market Competition Matrix, by Leading Players
14.3. List of Emerging, Prominent and Leading Players
14.4. Major Mergers & Acquisitions, Partnership, Joint Venture, Expansions, Deals, Recent Developments, etc.
15. Company Profiles
15.1. Generex Biotechnology
15.1.1. Company Overview & Insights
15.1.2. Financial Performance
15.1.3. Product / Service Portfolio
15.1.4. Geographical Footprint & Share
15.1.5. Strategic Initiatives & Key Developments
*Similar details would be provided for all the players mentioned below
15.2. Merck
15.3. BrightPath Biotherapeutics
15.4. Sellas
15.5. Ultimovacs
15.6. BioLife Science
15.7. Boston Biomedical
15.8. VAXON Biotech
15.9. Lytix Biopharma
15.10. ISA Pharmaceuticals
15.11. Sumitomo Dainippon Pharma
15.12. TapImmune
15.13. Onco Therapy Science
15.14. Enzo Life Science
15.15. Antigen Express
15.16. Galena Biopharma
15.17. Phylogica
15.18. Pfizer
15.19. Symphogen
15.20. Oncothyreon
15.21. BioLife Science
15.22. Immatics Biotechnologies
15.23. Immune Design
15.24. Others
16. Assumptions and Research Methodology
16.1. Data Mining
16.2. Secondary Research
16.3. Primary Research
16.4. Subject Matter Expert Advice
16.5. Quality Check
16.6. Final Review
16.7. Data Triangulation
16.8. Bottom-Up Approach
16.9. Top Down Approach
16.10. Research Flow
16.11. Key Insights from Industry Experts
16.12. Data Sources
16.13. Assumptions
16.14. Limitations
17. Conclusions and Recommendations
17.1. Key Research Findings and Conclusion
17.2. Key Insights & Recommendations from Analysts